| abstract |
Disclosed embodiments concern a combination comprising a JAK inhibitor and an immunooncology agent. The immunooncology agent may comprise an anti-PD- 1 antibody, anti- PD-L1 antibody, PI3K inhibitor, indole dioxygenase inhibitor or a combination thereof. The JAK inhibitor may be a pyrimidin-2-amine, 2,4-pyrimidinediamine, or a combination thereof. Also disclosed are embodiments of a method for using the combination to treat a subject, particularly a subject having a cell proliferative disorder. The method may further comprise administering one or more therapeutic agents in addition to the JAK inhibitor and immunooncology agent. Kits comprising the combination are also disclosed. |